HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions.

[1]  I. Frazer.  Interaction of human papillomaviruses with the host immune system: a well evolved relationship. , 2009, Virology.

[2]  G. Pawelec,et al.  Immunity, ageing and cancer , 2008, Immunity & Ageing.

[3]  Mark Jit,et al.  Economic evaluation of human papillomavirus vaccination in the United Kingdom , 2008, BMJ : British Medical Journal.

[4]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[5]  S. Wacholder,et al.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. , 2008, Journal of the National Cancer Institute.

[6]  M. Plummer,et al.  A 2-Year Prospective Study of Human Papillomavirus Persistence Among Women With a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion , 2008 .

[7]  S. Goldie,et al.  The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting , 2007, British Journal of Cancer.

[8]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[9]  S. Franceschi,et al.  Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.

[10]  Karen M Kuntz,et al.  Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.

[11]  N. Muñoz,et al.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. , 2007, The Lancet. Infectious diseases.

[12]  C. Signorelli,et al.  Age at first intercourse and HPV immunization. , 2007, Journal of preventive medicine and hygiene.

[13]  Marie-Claude Boily,et al.  Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. , 2007, American journal of epidemiology.

[14]  C. Wheeler,et al.  Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. , 2006, The Journal of infectious diseases.

[15]  C. Pasquarella,et al.  Third Italian national survey on knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health education campaigns. , 2006, European journal of public health.

[16]  S. Marshall,et al.  Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus , 2006, International journal of cancer.

[17]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. , 2006, The Lancet. Oncology.

[18]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. , 2006, Journal of the National Cancer Institute.

[19]  M. Lehtinen,et al.  Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses , 2006, PLoS medicine.

[20]  Helen Trottier,et al.  The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.

[21]  Helen Trottier,et al.  Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. , 2006, American journal of epidemiology.

[22]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[23]  R. Zanetti,et al.  Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992–98 , 2005, British Journal of Cancer.

[24]  S. Wacholder,et al.  Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.

[25]  S. Wacholder,et al.  A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.

[26]  N. Kiviat,et al.  Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.

[27]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[28]  A. Muñoz,et al.  Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. , 2004, The Journal of infectious diseases.

[29]  A. Moscicki,et al.  Regression of low-grade squamous intra-epithelial lesions in young women , 2004, The Lancet.

[30]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[31]  David I. Smith,et al.  Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes , 2004, Cancer Research.

[32]  R. Burk,et al.  Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women , 2004, Cancer Epidemiology Biomarkers & Prevention.

[33]  T. Rohan,et al.  Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. , 2003, Journal of the National Cancer Institute.

[34]  Michal Abrahamowicz,et al.  The natural history of type-specific human papillomavirus infections in female university students. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[35]  A. Giuliano,et al.  Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. , 2002, The Journal of infectious diseases.

[36]  W. Lawrence,et al.  Benefits and costs of using HPV testing to screen for cervical cancer. , 2002, JAMA.

[37]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[38]  N. Kiviat,et al.  Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[40]  C. Woodman,et al.  Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study , 2001, The Lancet.

[41]  H. Adami,et al.  A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. , 2000, Cancer research.

[42]  F. Coutlée,et al.  Detection of Human Papillomavirus Type 16 DNA in Consecutive Genital Samples Does Not Always Represent Persistent Infection as Determined by Molecular Variant Analysis , 2000, Journal of Clinical Microbiology.

[43]  H. Adami,et al.  Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study , 2000, The Lancet.

[44]  D C McCrory,et al.  Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. , 2000, American journal of epidemiology.

[45]  N. Kiviat,et al.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. , 2000, The Journal of infectious diseases.

[46]  A. Miller,et al.  Natural history of dysplasia of the uterine cervix. , 1999, Journal of the National Cancer Institute.

[47]  J. Dillner,et al.  Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. , 1999, The Journal of general virology.

[48]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[49]  Lydia P. Howell,et al.  NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS: A META‐ANALYSIS , 1998, Obstetrics and gynecology.

[50]  J. Cuzick,et al.  Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type , 1997, International journal of cancer.

[51]  A. Ponti,et al.  Interaction of spontaneous and organised screening for cervical cancer in Turin, Italy. , 1997, European journal of cancer.

[52]  C. Meijer,et al.  Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. , 1997, Journal of the National Cancer Institute.

[53]  H. Adami,et al.  International incidence rates of invasive cervical cancer before cytological screening , 1997 .

[54]  N. S. Murthy,et al.  Biological behaviour of moderate dysplasia--a prospective study. , 1996, Indian journal of cancer.

[55]  D. Clayton,et al.  Statistical Models in Epidemiology , 1993 .

[56]  J. Habbema,et al.  Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. , 1991, British Journal of Cancer.

[57]  D. K. Das,et al.  Natural history of precancerous and early cancerous lesions of the uterine cervix. , 1987, Acta cytologica.

[58]  H. Jones,et al.  The significance of basal-cell hyperactivity in cervical biopsies. , 1955, American journal of obstetrics and gynecology.

[59]  C. Woodman,et al.  The natural history of cervical HPV infection: unresolved issues , 2007, Nature Reviews Cancer.

[60]  Population Health Metrics BioMed Central , 2006 .

[61]  R. Anderson,et al.  Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. , 1994, IMA journal of mathematics applied in medicine and biology.

[62]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International Journal of Gynecological Pathology.